Cara Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
TVRD$1.410.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, | |||||||||
| · 2024 · 2023 · 2022 | |||||||||
| Operating activities · · · · · | |||||||||
| Net loss | | $(70,867) | | $(118,513) | | $(85,474) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | |||||
| Stock-based compensation expense | | 8,929 | | 13,730 | | 17,734 | |||
| Non-cash interest expense on liability related to sales of future royalties and milestones, net of issuance costs accretion | | | 8,473 | | | 604 | | | — |
| Impairment of long-lived assets | | | 4,274 | | | — | | | — |
| Inventory write-down | | | 2,963 | | | — | | | — |
| Depreciation and amortization | | 192 | | 259 | | 248 | |||
| Noncash lease expense | | 766 | | 2,075 | | 1,422 | |||
| (Accretion)/amortization of available-for-sale marketable securities, net | | | (543) | | | (400) | | | 264 |
| Changes in operating assets and liabilities: | | | | | | ||||
| Accounts receivable, net - related party | | | 2,358 | | | 495 | | | (3,260) |
| Inventory | | | (1,042) | | | (438) | | | 201 |
| Income tax receivable | | | 697 | | | — | | | — |
| Other receivables | | (1,034) | | (59) | | (41) | |||
| Prepaid expenses | | 7,625 | | 8,113 | | (13,748) | |||
| Accounts payable and accrued expenses | | (21,439) | | 3,275 | | 5,679 | |||
| Operating lease liabilities | | | (4,363) | | | (1,918) | | | (1,755) |
| Reimbursement of lease incentive | | | 2,094 | | | 807 | | | — |
| Other | | | — | | | (108) | | | — |
| Net cash used in operating activities | | (60,917) | | (92,078) | | (78,730) | |||
| Investing activities | | | | ||||||
| Proceeds from maturities of available-for-sale marketable securities | | 82,000 | | 155,441 | | 220,435 | |||
| Proceeds from redemptions of available-for-sale marketable securities, at par | | | — | | | 4,000 | | | 4,000 |
| Purchases of available-for-sale marketable securities | | (32,213) | | (113,605) | | (95,685) | |||
| Purchases of property and equipment | | | (1,046) | | | (2,375) | | | (43) |
| Net cash provided by investing activities | | 48,741 | | 43,461 | | 128,707 | |||
| Financing activities | | | | | |||||
| Payments to royalty purchase and sale agreement | | | (3,604) | | | — | | | — |
| Proceeds from royalty purchase and sale agreement, net of $1.0 million of issuance costs | | | — | | | 36,474 | | | — |
| Net proceeds from sales of common stock under open market sales agreement | | | — | | | 1,117 | | | — |
| Proceeds from the exercise of stock options | | — | | 560 | | 311 | |||
| Net cash (used in) provided by financing activities | | (3,604) | | 38,151 | | 311 | |||
| Net (decrease) increase in cash, cash equivalents and restricted cash | | (15,780) | | (10,466) | | 50,288 | |||
| Cash, cash equivalents and restricted cash at beginning of period | | 53,683 | | 64,149 | | 13,861 | |||
| Cash, cash equivalents and restricted cash at end of period | | $37,903 | | $53,683 | | $64,149 | |||
| Noncash investing and financing activities | | | | | | | | ||
| Receivable for additional HCR financing earned | | $2,500 | | $— | | $— | |||
| Incremental right-of-use asset in exchange for non-cash lease liability from modification of lease | | $3,417 | | $— | | $— | |||
| Transfer of property and equipment per lease assignment | | $(3,417) | | $— | | $— | |||
| Initial direct costs included as right-of-use asset from modification of lease | | $577 | | $— | | $— | |||
| Accrual for leasehold improvements | | $— | | $778 | | $— | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.